Detail akcie Agios Pharm online

Business Summary: Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Agios Pharmaceuticals Inc revenues increased from $8.7M to $20.7M. Net loss increased 11% to $99.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 3% to $110M, United States segment loss increase of 3% to $110M.